Icotinib: all 74 studies that test it

Page 1 of 1. Open to participants first (8), then studies with results posted, then the rest; newest registration first within each.

• Therapy for Advanced NSCLC With EGFR 19delins MutationNot yet recruitingNCT07458919Early Phase 1
• Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver MutationsNot yet recruitingNCT06955325Phase 3
• Befotertinib and Icotinib for NSCLC With Uncommon EGFR MutationsRecruitingNCT06517953Phase 2
• A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete ResectionNot yet recruitingNCT05514314Phase 2
• Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung AdenocarcinomaNot yet recruitingNCT05132985Phase 2
• A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung CancerRecruitingNCT05104788Phase 2
• Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.RecruitingNCT03992885Phase 3
• Adjuvant Chemotherapy With or Without Intercalated IcotinibNot yet recruitingNCT03983811Not applicable
• Icotinib for Completed Resected IB NSCLC With EGFR MutationCompletedNCT02264210Phase 2Results posted
• Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) PatientsCompletedNCT01040780Phase 3Results posted
• Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R MutationCompletedNCT05263947Phase 2
• Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung CancerActive, not recruitingNCT05007938Phase 2
• A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation TherapyStatus unknownNCT04058704Phase 3
• Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung CancerStatus unknownNCT03749213Phase 2
• Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLCCompletedNCT03736837Phase 2
• Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung CancerStatus unknownNCT03396185Phase 2
• Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung CancerStatus unknownNCT03349203Phase 2
• Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung CancerStatus unknownNCT03346811Phase 2
• Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate PsoriasisTerminatedNCT03222622Phase 2
• Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR MutationStatus unknownNCT03153358Phase 2
• Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) MutationStatus unknownNCT03151161Phase 2
• Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR MutationStatus unknownNCT02961270Phase 2
• High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLCStatus unknownNCT02960607Phase 2
• Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related TumorsCompletedNCT02934256Phase 2
• First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR MutationStatus unknownNCT02883543Phase 3
• The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR MutationStatus unknownNCT02820116Phase 2
• Icotinib Hydrochloride Cream in Patients With Mild to Moderate PsoriasisCompletedNCT02801435Phase 1
• Conmana Combined With Thalidomide to Treat NSCLCStatus unknownNCT02778893Phase 4
• Cryotherapy Combine Icotinib for Advanced NSCLC TreatmentCompletedNCT02744664Phase 4
• Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR MutationStatus unknownNCT02737774Phase 2
• High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain MetastasesStatus unknownNCT02726568Phase 2
• Icotinib Hydrochloride Cream in Healthy Adults and Psoriasis PatientsCompletedNCT02574091Phase 1
• Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With ChemotherapyCompletedNCT02486354Phase 3
• Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutationStatus unknownNCT02448797Phase 3
• Chemotherapy of NSCLC With or Without IcotinibStatus unknownNCT02430974Phase 2
• Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung CancerStatus unknownNCT02407366Phase 2
• High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon MutationStatus unknownNCT02404675Phase 4
• Phase II Study of Icotinib With Concurrent Radiotherapy in Elderly Patients With Esophageal CancerStatus unknownNCT02375581Phase 2
• Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR MutationsStatus unknownNCT02375022Phase 2
• Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line TherapyTerminatedNCT02362230Phase 2
• A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal CarcinomaStatus unknownNCT02328261Phase 2
• Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene MutationStatus unknownNCT02283424Phase 4
• Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic CancerStatus unknownNCT02278458Phase 1
• Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung CancerStatus unknownNCT02272127Phase 2
• Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung CancerStatus unknownNCT02215356Phase 2
• Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung CancerStatus unknownNCT02191059Phase 2
• Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung AdenocarcinomaStatus unknownNCT02125240Phase 3
• Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKIStatus unknownNCT02066870Phase 1
• Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic InsufficiencyStatus unknownNCT02062515Phase 2
• Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR MutationCompletedNCT02044328Phase 2
• Icotinib Hydrochloride in Treating Patients With Advanced CancersWithdrawnNCT02033148Phase 1
• High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable DiseaseStatus unknownNCT02027090Phase 2
• Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic CancerStatus unknownNCT02024633Phase 1
• Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung CancerStatus unknownNCT02009605Phase 2
• Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR MutationTerminatedNCT01996098Phase 3
• Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional ChemotherapyCompletedNCT01973725Phase 2
• Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target TherapyStatus unknownNCT01963195Phase 2
• Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR MutationStatus unknownNCT01929200Phase 2
• Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain MetastasesStatus unknownNCT01926171Phase 4
• Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISHCompletedNCT01855854Phase 2
• Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC PatientsStatus unknownNCT01843647Phase 2
• Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFRStatus unknownNCT01744925Phase 2
• Icotinib or Whole Brain Irradiation in EGFR-mutant Lung CancerCompletedNCT01724801Phase 3
• Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib TherapySuspendedNCT01720901Phase 4
• Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma PatientsCompletedNCT01719536Phase 3
• Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib TreatmentStatus unknownNCT01707329Phase 2
• Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable DiseaseStatus unknownNCT01690390Phase 2
• Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung CancerStatus unknownNCT01688713Phase 2
• Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung AdenocarcinomaStatus unknownNCT01665417Phase 4
• First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated PatientsStatus unknownNCT01646450Phase 4
• Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal CarcinomaCompletedNCT01534585Phase 1/2
• Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR MutationCompletedNCT01516983Phase 1/2
• Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung CancerCompletedNCT01514877Phase 2
• Dose Escalation Of Icotinib In Previously Treated Patients With Routine DoseCompletedNCT01465243Phase 4

← Icotinib overview